Top news from MedWatch this week
Monday
Genmab CEO spots potential in Amgen’s billion-dollar Horizon acquisition
Lundbeck CEO looks to a near future undisturbed by patent expiration
Secondary industry to spring from Novo Nordisk’s Danish Wegovy launch
FDA warns of shortage of Eli Lilly’s diabetes drugs
Tuesday
Pfizer gets hands on another RSV candidate through existing deal
Danish Health Authority: Wegovy should play a ”smaller role” in obesity treatment
Ambu chair dispels power shift concerns after founder heir joins board
Wednesday
UK competition authority escalates investigation of Oticon Medical sale
Genmab and Abbvie file for cancer drug approval in Japan
R&D head retires after 19 years at ALK: ”We created the modern ALK”
Thursday
Novo Nordisk buys access to try out long-acting injection technology
GN Group CFO quits – replacement found at ALK
Friday
Novo Nordisk ends 2022 triumphantly – and next year is looking even better
Bavarian Nordic enters agreement with US defense department
Leo Pharma wins Japanese approval to launch and manufacture main asset
